CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...